Rates, predictors, and mortality of sepsis-associated acute kidney injury: a systematic review and meta-analysis

Jiefeng Liu¹, Hebin Xie², Ziwei Ye³, Fen Li³ and Lesan Wang¹*

Abstract

Background: Due to the high incidence and mortality of sepsis-associated acute kidney injury, a significant number of studies have explored the causes of sepsis-associated acute kidney injury (AKI). However, the opinions on relevant predictive risk factors remain inconclusive. This study aimed to provide a systematic review and meta-analysis to determine the predisposing factors for sepsis-associated AKI.

Method: A systematic literature search was performed in the Medline, Embase, Cochrane Library, PubMed, and Web of Science, databases, with an end-date of 25th May 2019. Valid data were retrieved in compliance with specific inclusion and exclusion criteria.

Result: Forty-seven observational studies were included for analysis, achieving a cumulative patient number of 55,911. The highest incidence of AKI was caused by septic shock. Thirty-one potential risk factors were included in the meta-analysis. Analysis showed that 20 factors were statistically significant. The odds ratio (OR) and 95% confidence interval (CI), as well as the prevalence of the most frequently-seen predisposing factors for sepsis-associated AKI, were as follows: septic shock [2.88 (2.36–3.52), 60.47%], hypertension [1.43 (1.20–1.70), 38.39%], diabetes mellitus [1.59 (1.47–1.71), 27.57%], abdominal infection [1.44 (1.32–1.58), 30.87%], the administration of vasopressors [2.95 (1.67–5.22), 64.61%], the administration of vasoactive drugs [3.85 (1.89–7.87), 63.22%], mechanical ventilation [1.64 (1.24–2.16), 68.00%], positive results from blood culture [1.60 (1.35–1.89), 41.19%], and a history of smoking [1.60 (1.09–2.36), 43.09%]. Other risk factors included cardiovascular diseases, coronary artery diseases, liver diseases, unknown infections, the administration of diuretics and ACEI/ARB, the infection caused by gram-negative bacteria, and organ transplantation.

Conclusion: Risk factors of S-AKI arise from a wide range of sources, making it difficult to predict and prevent this condition. Comorbidities, and certain drugs, are the main risk factors for S-AKI. Our review can provide guidance on the application of interventions to reduce the risks associated with sepsis-associated acute kidney injury and can also be used to tailor patient-specific treatment plans and management strategies in clinical practice.

Keywords: Acute kidney injury, Sepsis, Risk factor, Meta-analysis, Systematic review

* Correspondence: wlshncs@126.com
1Department of epidemiology and health statistics, Xiangya School of public health, Central South University, No. 238, Mayuanling Lane, Furong Middle Road, Kaifu District, Changsha City, Hunan Province, China
Full list of author information is available at the end of the article
Background
Sepsis-associated acute kidney injury (S-AKI) is a major public health condition that is associated with a significant disease burden. S-AKI is a syndrome of acute functional impairment and organ damage that could be associated with long-term adverse outcomes. Sepsis is the most common cause of acute kidney injury (AKI) in critically ill patients, and is observed in 40–50% of patients with AKI [1–4]. Of particular importance is the fact that S-AKI is closely associated with poor clinical outcomes. For instance, the mortality rate of sepsis patients with AKI complications is significantly higher than that of non-AKI patients [5]. Among critically ill patients with AKI, S-AKI is correlated with a higher risk of inhospital death and longer durations in hospital than AKI caused by any other reasons [3]. Despite significant advances in medicine and surgical treatment, the morbidity associated with this condition remains rather high. Mounting evidence suggests that the incidence of AKI incidence is steadily increasing. A previous 10-year cohort study, including more than 90,000 patients from more than 20 ICUs, indicated that the incidence of AKI incidence has increased by 2.8% per year [1]. Moreover, along with the global trend for aging, the majority of patients with sepsis are elderly; furthermore, the number of patients with sepsis-associated AKI is likely to continue to increase [6, 7]. Sepsis-associated AKI is associated with a high burden of morbidity and mortality in both children and adults with critical illness. Unfortunately, the pathogenesis of S-AKI is still not completely understood. There are also difficulties in the early diagnosis and treatment of S-AKI that need to be solved. Therefore, it is vital that we develop tools to identify the risk factors of S-AKI early so that we can attempt to prevent this disease. Although a number of studies have explored the risk factors associated with the development of AKI in patients with sepsis, clinical opinions remain inconclusive due to regional differences and inconsistencies in the diagnostic criteria relating to sepsis and AKI. In this study, we aimed to systematically review previous observational studies (cohort/case-control studies) and to perform meta-analyses with the eligible evidence to investigate the association between sepsis and AKI.

Methods
Inclusion criteria
Studies that met the following criteria were included for data extraction: (1) Patients needed to be older than 16 years with a hospitalization stay of greater than 24 h; (2) Studies needed to contain information presented in a 2 × 2 contingency table; (3) Sepsis and septic shock needed to be diagnosed using internationally-recognized standards, such as KDIGO, AKIN, and RIFLE; (5) Cohort or case-control studies needed the patients to be grouped into sepsis with AKI and sepsis without AKI.

Data sources and search strategy
A systematic review and meta-analysis of scientific peer-reviewed literature was performed by following the recommendations from the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) guideline [11]. The systematic literature search was performed in Medline, Embase, Cochrane Library, PubMed, and Web of Science, databases from inception to June 2019 with no restrictions. The search aimed to retrieve studies that assessed the risk of AKI development in patients with sepsis. The following search terms were used: (septic OR sepsis OR severe sepsis OR Septicemia OR septic shock OR sepsis-associated OR sepsis-associated) AND (Acute Kidney Injury OR Acute Renal Injury OR Acute Renal Insufficiency OR AKI OR acute renal failure OR ARF). The reference lists of the included articles were also manually retrieved. We did not include gray literature (literature that has not published) or conference abstracts.

Data extraction
Two independent reviewers participated in the entire process of literature retrieval. First-round screening was performed based on the title and abstract so that we could exclude studies on irrelevant topics. Next, the included articles were screened based on full text; non-eligible articles that did not meet the inclusion criteria were excluded. Data extraction was performed using a standardized data collection form, including: (1) study characteristics: publication year, study design, country of origin, diagnostic criteria for sepsis and acute kidney injury, type of sepsis, period of data report; (2) the number of 2 × 2 contingency tables and unadjusted crude odds ratios with regards to demographic data (gender) and the independent variables/predictors under investigation (comorbidities, source of infection, medication, invasive treatment, types of sepsis, and blood culture); and (3) outcome: the primary endpoint was S-AKI; the secondary outcome was the prevalence of influential factors and mortality in patients with S-AKI.

Quality assessment
Study selection, data extraction, and quality assessments were independently performed by two authors. Any disagreements were resolved through discussions until a consensus was reached. If disagreements persisted, another reviewer would be invited to the discussion to achieve a final consensus. Quality assessment of the
observational studies that were included in the meta-
analysis was performed using the Newcastle-Ottawa
scale (available at http://www.ohri.ca/programs/clinical_ 
epidemiology/oxford.asp).

Statistical analysis
The core characteristics of the study and patients were
sorted and summarized. The frequency distribution
expressed as a percentage. For meta-analysis, we only
used non-adjusted crude odds ratios (OR) from no less
than 3 studies to standardize the results; this was due to
the significant variability of multivariable models across
different studies. Stata/SE version 11 was used for all
statistical analyses and a two-sided \( P \) value of 0.05 or less
was considered to be statistically significant. Heterogen-
ey among studies was evaluated by calculating the \( I^2 \)
statistic (significance level was set to \( I^2 > 50\% \)) and chi-
squared value (significance level set to \( P < 0.10 \)). \( I^2 \) values
of 25 and 75\% were used as the criteria for classifying
the degree of inter-trial heterogeneity (\( I^2 < 25\% \): low het-
erogeneity; \( I^2 > 25\% \) and < 75\%: moderate heterogeneity: \( I^2 > 75\% \): high heterogeneity). If severe heterogeneity was
present at \( I^2 > 50\% \), then a random-effects model was se-
lected, otherwise the fixed-effects model was used. For
results with a heterogeneity of < 50\% and a fixed-effects
model, the stability would be explored by transformation
into a random-effects model. Meta regression and sub-
group analyses (\( \geq 6 \) studies) were conducted according
to publication year, study design, country of origin, sep-
sis type, and the diagnostic criteria used for acute kidney
injury and sepsis, on the condition of high inter-trial heterogeneity (\( I^2 > 50\% \) and \( P < 0.10 \)). Sensitivity analysis
of the overall risk (\( \geq 3 \) studies) was conducted by omit-
ting 1 study each time in order to estimate the impact of
individual studies. Publication bias was examined visu-
ally by the use of funnel plots, and the Egger’s test was
used to carry out asymmetric tests on the pooled data of
\( \geq 7 \) studies.

Results
Literature search (Fig. 1)
In total, 8033 records were initially identified from the
Medline, Embase, Cochrane Library, PubMed, and Web
of Science, databases. By filtering the title and abstract,
we were able to exclude duplicate articles, review studies, and studies on unrelated topics. In total, the full text of 626 studies was reviewed. After excluding comment papers, studies with inconsistent control settings, articles with unspecified AKI or sepsis diagnostic criteria, studies performed in special populations, and those with limited data, 47 articles met the inclusion criteria and were included in the systematic review and meta-analysis.

**Characteristics of the included studies (Table 1)**
The characteristics of the included articles are shown in Table 1. Studies were published between 2008 and 2019 and originated from 18 countries (Spain, Greece, United Kingdom, France, Netherlands, Sweden, Canada, United States, Brazil, China, Japan, Saudi Arabia, Turkey, Finland, Portugal, South Korea and Australia) on four continents (Europe, America, Asia and Oceania). Overall, we included 12 retrospective cohort studies, 25 prospective cohort studies, and 12 case-control studies, with a total of 55,911 patients with sepsis. Document quality assessment showed that the methodological quality of all of the included studies was high, achieving a quality score of 8 (≥ 6).

**Summary data from the included studies (Table 2)**
This study summarized the characteristics of sepsis patients who developed AKI. ICU mortality, hospital mortality, 28-day mortality, and 90-day mortality, of patients with S-AKI were respectively reported at 45.99% (1989/4325 cases) in 15 studies, 49.84% (2732/5481) in 10 studies, 36.67% (161/439) in 4 studies, and 64.66% (2406/3721) in 5 studies, respectively. In S-AKI patients, the highest mortality rate for AKI was caused by septic shock; severe sepsis was associated with the lowest mortality rate.

The most prevalent comorbidity was ARDS (47.02%; 489/1040; from 3 studies), followed by hypertension (38.39%; 3263/8500; from 32 studies), diabetes (27.57%; 2248/8155; from 32 studies) and stroke (22.79%; 67/294; from 4 studies), while cirrhosis and liver disease accounted for only 4.71% (99/2104; from 6 studies) and 3.74% (554/14081; from 7 studies), respectively. Hepatic failure was more common in patients with sepsis compared with those with septic shock and severe sepsis. Hypertension in patients with septic shock was less common than sepsis and severe sepsis (26.16% vs 42.28 and 58.07%), while chronic kidney disease was more prevalent (45.13% vs 15.52 and 11.02%). Hypertension and diabetes were more prevalent in patients with severe sepsis than in sepsis and septic shock (58.7% vs 42.28 and 26.16%, 30.20% vs 20.53 and 26.75%).

On admission, patient source mainly included emergency admission (50.88%; 9235/18149; from 8 studies) and medical admission (47.02%; 8701/18506; from 7 studies), followed by operative admission and surgical ward. Vasoactive drugs were the most commonly used drugs, accounting for 64.61% of cases (1293/2001; from 5 studies), of which vasopressors were the most frequently used, accounting for 63.22% of cases (911/1441; from 7 studies), followed by steroids, diuretics, ACEI or ARB, stains, and NSAIDS. Vasoactive drugs and vasopressors were more prevalent in patients with septic shock and severe sepsis than in patients with sepsis.

Six sources of infection were reported in this study, including pulmonary infection (46.05%; 1480/3214; from 19 studies), respiratory infection (32.08%; 85/273; from 7 studies), abdominal infection (30.87%; 2152/6971; from 25 studies), urinary tract infection (11.14%; 630/5653; from 19 studies), skin or soft tissue infection (6.03%; 335/5554; from 13 studies), and unknown infections (6.02%; 100/1662; from 4 studies).

Community acquired infection was reported in 3 studies with a prevalence of 57.36% (2041/3558), which was higher than nosocomial acquired infection, reported in 2 studies (39.81%; 2474/6215). Twenty-four studies reported mechanical ventilation in 68.00% of patients (7167/10539; from 24 studies), and mechanical ventilation was more frequently used in patients with septic shock and severe sepsis compared with patients with sepsis. Other prevalent factors included positive blood culture (41.38%; 3259/7876; from 8 studies) and smoking history (43.09%; 642/1490; from 5 studies).

**Risk factors for AKI (Fig. 2)**

**Comorbidities**
Pooled data from 32 studies indicated that hypertension was a significant predictor (OR: 1.43; 95% CI: 1.20–1.70) with moderate heterogeneity (I² = 74.00%). The source of heterogeneity was not identified by subgroup analysis.

The results of the sensitivity analyses were consistent. After excluding 3 studies with rather high heterogeneity, the level of heterogeneity decreased, and the result remained stable (see Additional file 2).

Pooled data from 32 studies indicated that diabetes mellitus was a significant predictor (OR: 1.59; 95% CI: 1.47–1.71) with moderate heterogeneity (I² = 37.1%). The results remained stable even with a random-effects model (see Additional file 3).

Pooled data from 14 studies indicated that chronic kidney disease was a significant predictor (OR: 3.49; 95% CI: 2.36–5.15) with moderate heterogeneity (I² = 71.70%). The source of heterogeneity was not identified by subgroup analysis. The results of sensitivity analyses were consistent. After excluding one study with high heterogeneity, I² was reduced to 25.6% (low heterogeneity) and the result remained stable (see Additional file 4).

Cardiovascular disease (from 14 studies; OR: 1.31; 95% CI: 1.24–1.40) and liver disease (from 17 studies; OR:
Table 1: Characteristics of included studies in systematic review and meta-analysis

| Author             | Publication year | Country | AKI diagnostic criteria | Sepsis types                         | Study period         | Research design                  | Numble AKI VS No AKI | Quality score |
|--------------------|------------------|---------|-------------------------|---------------------------------------|----------------------|----------------------------------|----------------------|---------------|
| Bu et al. [12]     | 2019             | China   | KDIGO                   | Sepsis and Septic shock                | 2015–2017            | Retrospective case-control study | 132/90               | 7             |
| Hsu et al. [13]    | 2019             | China   | AKIN                    | Sepsis                               | 2012–2016            | Retrospective case-control study | 99/597               | 6             |
| Vlinder et al. [14]| 2019             | Finland | KDIGO                   | Sepsis                               | 2011–2012            | Prospective cohort study         | 300/353              | 7             |
| Xing et al. [15]   | 2019             | China   | KDIGO                   | Septic shock                         | 2018.8–2018.11       | Prospective cohort study         | 29/43                | 8             |
| Moman et al. [16]  | 2018             | USA     | KDIGO                   | Septic shock                         | 2007–2009            | Retrospective cohort study       | 160/73               | 8             |
| Zhi et al. [17]    | 2018             | China   | AKIN                    | Sepsis                               | 2009–2015            | Retrospective case-control study | 315/267              | 5             |
| Zhou et al. [18]   | 2018             | China   | AKIN                    | Sepsis                               | 2010–2017            | Retrospective case-control study | 405/348              | 7             |
| Costa et al. [19]  | 2018             | Brazil  | KDIGO                   | Septic shock                         | 2014–2015            | Prospective cohort study         | 66/63                | 7             |
| Song et al. [20]   | 2018             | China   | KDIGO                   | Sepsis                               | 2015–2016            | Prospective cohort study         | 52/72                | 7             |
| Hu et al. [21]     | 2018             | China   | RIFLE                   | Severe sepsis and Septic shock       | 2016–2017            | Prospective cohort study         | 52/53                | 8             |
| Fatani et al. [22] | 2018             | Saudi Arabia | RIFLE                 | Severe sepsis and Septic shock     | 2016–2017            | Prospective cohort study         | 127/73               | 7             |
| Gameiro et al. [23]| 2017             | Portugal | KDIGO                   | Sepsis and Septic shock              | 2008–2014            | Retrospective case-control study | 399/57               | 6             |
| Katayama et al. [24]| 2017            | Japan   | KDIGO                   | Sepsis                               | 2011–2016            | Retrospective case-control study | 163/351              | 7             |
| Vlinder et al. [25]| 2017             | Finland | KDIGO                   | Septic shock                         | 2011–2012            | Prospective cohort study         | 252/226              | 7             |
| Suberviola et al. [26]| 2017          | Spain   | KDIGO                   | Septic shock                         | 2005–2010            | Prospective cohort study         | 312/74               | 7             |
| Fisher et al. [27] | 2017             | Sweden  | KDIGO                   | Septic shock                         | –                    | Prospective cohort study         | 225/71               | 6             |
| Pérez-Fernández et al. [28]| 2017      | USA     | KDIGO                   | Severe sepsis and Septic shock      | 2005–2007            | Prospective cohort study         | 82/178               | 7             |
| Pereira et al. [29]| 2017             | Portugal | RIFLE                   | Severe sepsis and Septic shock      | 2008–2014            | Retrospective case-control study | 384/72               | 7             |
| Panich et al. [30] | 2017             | Thailand | AKIN                    | Sepsis                               | 2014–2014            | Prospective cohort study         | 79/60                | 7             |
| Su et al. [31]     | 2016             | China   | KDIGO                   | Severe sepsis                        | –                    | Prospective cohort study         | 45/27                | 6             |
| Yilmaz et al. [32] | 2015             | Turkey  | AKIN                    | Severe sepsis                        | 2011–2013            | Retrospective cohort study       | 68/50                | 7             |
| Medeiros et al. [33]| 2015           | Japanese | AKIN                    | Sepsis                               | 2013–2014            | Retrospective cohort study       | 144/56               | 8             |
| Dai et al. [34]    | 2015             | China   | KDIGO                   | Sepsis                               | 2012–2014            | Prospective cohort study         | 55/57                | 7             |
| Sood et al. [35]   | 2014             | Canada  | RIFLE                   | Septic shock                         | 1996–2008            | Prospective cohort study         | 3298/1195            | 7             |
| Peng et al. [36]   | 2014             | China   | KDIGO                   | Sepsis                               | 2008–2011            | Prospective cohort study         | 101/110              | 8             |
| Patschan et al. [37]| 2014          | Germany | AKIN                    | Sepsis                               | –                    | Retrospective case-control study | 22/11                | 7             |
| Tu et al. [38]     | 2014             | China   | AKIN                    | Sepsis                               | 2011–2013            | Prospective cohort study         | 49/101               | 6             |
| Fan et al. [39]    | 2014             | China   | RIFLE                   | Sepsis                               | 2012–2014            | Prospective cohort study         | 58/67                | 7             |
| CHO et al. [40]    | 2014             | Korea   | RIFLE                   | Sepsis                               | 2010–2011            | Prospective cohort study         | 44/18                | 7             |
| Author                  | Publication year | Country      | AKI diagnostic criteria | Sepsis types                      | Study period    | Research design                        | Numble AKI VS No AKI | Quality score |
|-------------------------|------------------|--------------|-------------------------|-----------------------------------|----------------|----------------------------------------|----------------------|---------------|
| Terzi et al. [41]       | 2014             | Greece       | RIFLE                   | Sepsis                            | –              | Prospective cohort study               | 16/29                | 6             |
| Poukkonen et al. [42]   | 2013             | Finland      | KDIGO                   | Severe sepsis                     | 2011–2012      | Retrospective case-control study        | 153/270              | 7             |
| Legrand et al. [43]     | 2013             | France       | AKIN                    | Severe sepsis and Septic shock    | 2006–2010      | Prospective cohort study               | 69/68                | 8             |
| Cardinal-Fernández et al. [44] | 2013        | Spain        | RIFLE                   | Severe sepsis                     | 2005–2008      | Prospective cohort study               | 65/74                | 7             |
| de Geus et al. [45]     | 2013             | Netherlands  | AKIN                    | Sepsis                            | 2007–2008      | Prospective cohort study               | 49/432               | 7             |
| Katagiri et al. [46]    | 2013             | Japan        | RIFLE                   | Sepsis                            | 2010–2011      | Prospective cohort study               | 24/10                | 6             |
| Aydogdu et al. [47]     | 2013             | Turkey       | RIFLE                   | Sepsis                            | 2008–2010      | Prospective cohort study               | 63/66                | 7             |
| Suh et al. [48]         | 2013             | South Korea  | RIFLE                   | Sepsis and Septic shock           | 2010           | Retrospective case-control study        | 573/419              | 8             |
| Poukkonen et al. [49]   | 2013             | Finland      | KDIGO                   | Severe sepsis                     | 2011–2012      | Retrospective case-control study        | 437/393              | 7             |
| Zhao et al. [50]        | 2013             | China        | AKIN                    | Sepsis                            | 2011–2013      | Retrospective case-control study        | 90/58                | 6             |
| Payen et al. [51]       | 2012             | Brazil       | AKIN                    | Severe sepsis and Septic shock    | 2004–2005      | Retrospective cohort study               | 129/47               | 6             |
| Frank et al. [52]       | 2012             | USA          | AKIN                    | Septic shock                      | 1999–2009      | Retrospective cohort study               | 627/637              | 7             |
| Plataki et al. [53]     | 2011             | USA          | RIFLE                   | Septic shock                      | 2005–2007      | Retrospective cohort study               | 237/153              | 7             |
| Maårtensson et al. [54] | 2010             | Sweden       | RIFLE OR AKIN           | Septic shock                      |                 | Prospective cohort study               | 18/7                 | 6             |
| YANG et al. [55]        | 2009             | China        | AKIN                    | Septic shock                      | 2001–2008      | Retrospective cohort study               | 126/32               | 7             |
| Lopes et al. [56]       | 2009             | Portugal     | AKIN                    | Sepsis                            | 2004–2007      | Retrospective cohort study               | 99/216               | 7             |
| Bagshaw et al. [57]     | 2009             | Canada, the United States and Saudi Arabia | RIFLE | Septic shock | 1989–2005 | Retrospective cohort study               | 2917/1615            | 7             |
| Bagshaw et al. [58]     | 2008             | Australia    | RIFLE                   | Sepsis                            | 2000–2005      | Retrospective cohort study               | 14039/19336          | 8             |
| Characteristic                  | No.Studies | Prevalence | Sepsis | Prevalence | Septic shock | Prevalence | Severe sepsis | Prevalence |
|--------------------------------|------------|------------|--------|------------|--------------|------------|---------------|------------|
|                               |            |            | No.Studies |            | Yes.Studies |            | Yes.Studies |            |
| Septic AKI                     | 47         | 48.73% (27,248/55911) | 22       | 41.98% (16,399/39067) | 12       | 60.47% (12,678/20965) | 5       | 38.92% (768/1570) |
| Sex (male)                     | 44         | 59.70% (5913/9904) | 22       | 63.68% (1380/2167) | 11       | 59.64% (3191/5350) | 5       | 64.45% (495/768) |
| Comorbidities                  |            |            |        |            |              |            |                |            |
| Hypertension                   | 32         | 38.39% (3263/8500) | 14       | 42.28% (859/1817) | 6        | 26.16% (1073/4102) | 5       | 58.07% (446/768) |
| Diabetes mellitus              | 32         | 27.57% (2248/8155) | 13       | 20.53% (373/1817) | 7        | 26.75% (1897/7091) | 5       | 30.20% (232/768) |
| Stroke                         | 4          | 22.79% (67/294) | 1        | 22.33% (67/300) |          | –            | –        | 17.78% (8/45) |
| Cancer                         | 6          | 18.23% (705/3745) |          | –            | 2        | 18.80% (650/3548) | 1       | 16.33% (8/49) |
| Chronic kidney disease         | 14         | 16.46% (449/2795) | 7        | 15.52% (178/1147) | 2        | 45.13% (102/226) | 2       | 11.02% (65/590) |
| Cardiovascular disease         | 11         | 16.30% (2522/15477) | 4       | 19.47% (169/868) |          | –            | –        | 7.00% (3/45) |
| Congestive heart failure       | 7          | 12.69% (491/3869) | 2        | 17.26% (39/226) | 4        | 12.64% (446/3529) | 1       | 8.80% (6/68) |
| COPD                           | 17         | 12.41% (1114/8976) | 6        | 12.69% (90/709) | 5        | 12.99% (873/6721) | 1       | 5.20% (25/437) |
| Hepatic failure                | 4          | 12.16% (449/3691) | 2        | 39.76% (134/337) | 1        | 9.90% (290/2917) | 3       | 12.61% (83/658) |
| Coronary artery disease        | 8          | 11.58% (4573/3948) | 4        | 10.14% (88/868) | 2        | 9.30% (274/2946) | 1       | 6.15% (4/68) |
| Systolic heart failure         | 4          | 11.25% (135/1200) | 1        | 8.00% (24/300) | 2        | 14.32% (59/412) | 1       | 11.90% (52/437) |
| Immunosuppression              | 7          | 10.35% (1888/18249) | 4       | 12.74% (1300/14204) | 3       | 15.80% (550/3481) | 1       | 7.20% (35/437) |
| Cirrhosis                      | 6          | 4.71% (99/2104) | 1        | 1.73% (7/405) | 2        | 7.50% (59/787) | –        | –          |
| Liver disease                  | 7          | 3.74% (554/14081) | 3        | 3.57% (509/14282) | 1        | 8.73% (22/252) | 2       | 8.59% (17/198) |
| Admission category             |            |            |        |            |              |            |                |            |
| Emergency admission            | 7          | 50.88% (9235/18149) | 2       | 50.90% (7298/14339) | 2       | 41.46% (1314/3169) | 2       | 97.12% (573/590) |
| Medical admission              | 8          | 47.02% (8701/18506) | 3       | 49.16% (6938/14112) | 2       | 36.99% (1311/3544) | –       | –          |
| Operative admission            | 5          | 30.91% (353/1142) | 1        | 22.33% (67/300) | 1        | 23.02% (58/252) | 2       | 28.81% (170/590) |
| Surgical ward                  | 7          | 17.73% (3787/21359) | 3       | 16.51% (2375/14388) | 3       | 21.29% (1380/6482) | –       | –          |
| Source of infection            |            |            |        |            |              |            |                |            |
| Pulmonary                      | 19         | 46.05% (1480/3214) | 8       | 57.96% (448/773) | 5       | 41.10% (603/1467) | 3       | 48.02% (316/658) |
| Respiratory                    | 7          | 32.08% (273/85) | 2        | 41.22% (54/131) | 2        | 32.74% (74/226) | 2       | 26.36% (29/110) |
| Abdominal                      | 25         | 30.87% (2152/6971) | 7        | 32.12% (177/551) | 7        | 28.16% (1253/4450) | 5       | 28.65% (220/768) |
| Urinary tract                  | 19         | 11.14% (630/5653) | 6        | 12.01% (58/483) | 6        | 11.34% (483/4259) | 5       | 11.38% (80/703) |
| Skin or soft tissue            | 13         | 6.03% (335/5554) | 3        | 2.15% (5/232) | 4        | 5.40% (218/4033) | 3       | 10.71% (68/635) |
| Unknown                        | 4          | 6.02% (100/1662) |          | –            | 2        | 8.30% (73/879) | –       | –          |
| Community acquired             | 3          | 57.36% (2041/3558) |          | –            | 1        | 56.80% (1657/2917) | 2       | 65.08% (384/590) |
| Nosocomial acquired            | 2          | 39.81% (2474/6215) |          | –            | 2        | 39.81% (2474/6215) | –       | –          |
| Medications                    |            |            |        |            |              |            |                |            |
| Characteristic | No. Studies | Prevalence | Sepsis No. Studies | Prevalence | Septic shock No. Studies | Prevalence | Severe sepsis No. Studies | Prevalence |
|---------------|------------|------------|-------------------|------------|--------------------------|------------|--------------------------|------------|
| Vasopressors  | 7          | 64.61% (1293/2001) | 3                  | 45.04% (100/222) | 2                  | 59.38% (513/864) | –            | –          |
| Vasoactive drugs | 5          | 63.22% (911/1441) | 2                  | 35.69% (131/367) | 1                  | 67.50% (108/160) | 2            | 96.44% (569/590) |
| Steroids      | 3          | 30.80% (85/276)   | 2                  | 38.16% (79/207)  | –                  | –            | –            | –          |
| Diuretics     | 4          | 30.77% (296/962)  | –                  | –            | 1                  | 39.40% (97/252)  | 2            | 30.85% (182/590) |
| ACEI or ARB   | 8          | 25.62% (619/2416) | 1                  | 18.41% (58/315)  | 3                  | 24.97% (200/801) | 3            | 33.59% (220/655) |
| Stains        | 5          | 21.77% (357/1640) | –                  | –            | 2                  | 24.74% (118/489) | 1            | 15.79% (69/437)  |
| Nsaids        | 9.63% (203/2108) | 1                  | 16.19% (51/315)  | 2            | 11.45% (56/489)  | 2            | 12.54% (74/590)  |
| Bacteria      |            |            |                  |            |            |            |            |            |
| Gram-negative bacteria | 3          | 17.26% (160/927)  | –                  | –            | 1                  | 22.3% (49/225)  | –            | –          |
| Gram-positive bacteria | 4          | 10.43% (99/949)  | 1                  | 18.20% (4/22)   | 1                  | 28.6% (63/225)  | –            | –          |
| Invasive treatment |        |            |                  |            |            |            |            |            |
| Mechanical ventilation | 23         | 68.00% (7167/10539) | 7                  | 49.17% (415/844) | 6                  | 71.21% (5481/7643) | 4            | 75.25% (529/703) |
| Renal replacement therapy | 6          | 39.51% (320/810)  | 1                  | 36.53% (19/52)  | 1                  | 18.18% (12/66)  | –            | –          |
| Dialysis      | 3          | 28.92% (59/204)   | 2                  | 35.04% (48/137) | –                  | –            | –            | –          |
| Blood transfusion | 3          | 19.46% (94/483)  | 1                  | 7.64% (11/144)  | 2                  | 27.49% (3/303)  | –            | –          |
| Organ transplant | 3          | 3.76% (252/6703) | –                  | –            | 2                  | 3.94% (245/6215) | 1            | 1.6% (7/437)  |
| Positive blood culture | 8          | 41.38% (3259/7876) | –                  | –            | 4                  | 42.8% (2836/6612) | 2            | 30.29% (146/482) |
| Bloodstream infection | 4          | 6.61% (237/3586)  | 1                  | 17.31% (9/52)  | 1                  | 7.4% (216/2917) | 1            | 4.7% (6/487)  |
| Smoke history | 5          | 43.09% (642/1490) | 2                  | 40.42% (291/720) | –                  | –            | 1            | 32.35% (22/68) |
| ARDS          | 3          | 47.02% (489/1040) | 1                  | 81.19% (82/101) | 2                  | 43.34% (407/939) | –            | –          |
| Multiorgan dysfunction (≥3) | 3          | 50.11% (436/870)  | 1                  | 70.48% (222/315) | –                  | –            | –            | –          |
| Mortality     |            |            |                  |            |            |            |            |            |
| ICU mortality | 10         | 45.99% (1989/4325) | 2                  | 50.00% (46/92)  | 4                  | 50.47% (16/72/3313) | 1            | 35.38% (23/65) |
| Hospital mortality | 15         | 49.84% (2732/5481) | 7                  | 42.17% (245/581) | 3                  | 55.83% (1935/3466) | 1            | 29.29% (128/437) |
| 28-day mortality | 4          | 36.67% (161/439)  | 1                  | 30.61% (15/49)  | 1                  | 71.42% (90/126)  | –            | –          |
| 90-day mortality | 5          | 64.66% (2406/3721) | –                  | –            | 1                  | 58.42% (1704/2917) | 2            | 40.0% (236/590) |

COPD chronic obstructive pulmonary disease, ACEI or ARB angiotensin converting enzyme inhibitors or Angiotensin Receptor Blocker, ARDS acute respiratory distress syndrome
1.68; 95% CI: 1.47–1.90) were identified as risk factors with low levels of heterogeneity. The results remained stable even with a random-effects model (see Additional files 5 and 6).

Pooled data from 8 studies indicated that coronary artery disease was a significant predictor (OR: 1.27; 95% CI: 1.08–1.49) with moderate heterogeneity ($I^2 = 37.1\%$). The results remained stable with the random-effects model (see Additional file 7).

**Source of infection**

Pooled data from 25 studies indicated that abdominal infection was a significant predictor (OR: 1.44; 95% CI: 1.32–1.58) with moderate heterogeneity ($I^2 = 40.2\%$). The results of the sensitivity analyses were consistent. After excluding one study with high levels of heterogeneity, the results remained stable; the results were also stable with the fixed-effects model (see Additional file 9).

Pooled data from 25 studies indicated that unknown infection was a significant predictor (OR: 2.01; 95% CI: 0.60–0.99) with moderate heterogeneity ($I^2 = 77.60\%$). The source of heterogeneity was not identified by subgroup analysis. The results of sensitivity analyses were consistent (see Additional file 8).

| Risk factor                        | Pooled OR (95% CI) | Forest map | No. Studies | Univariable | Pooled | Measure of Heterogeneity |
|-----------------------------------|--------------------|------------|-------------|-------------|--------|-------------------------|
| Sex (male)                        | 1.22 (1.06-1.40)   |            | 43          | 10          | 60.43%  | 0.049 0.521             |
| Septic shock                      | 2.88 (2.36-3.32)   |            | 7           | 0           | 66.37%  | 0.536 0.26%             |
| Positive blood culture            | 1.60 (1.35-1.89)   |            | 9           | 5           | 41.13%  | 0.041 0.525             |
| Smoking history                   | 1.60 (1.09-2.36)   |            | 5           | 3           | 43.09%  | 0.001 78.3%             |
| Bloodstream infection             | 0.99 (0.80-1.24)   |            | 4           | 4           | 6.61%   | 0.427 0.006             |
| Comorbidities                     |                    |            |             |             |        |                         |
| Hypertension                      | 1.43 (1.20-1.70)   |            | 32          | 10          | 58.39%  | 0.749 0.374             |
| Diabetes mellitus                 | 1.59 (1.47-1.71)   |            | 32          | 11          | 27.57%  | 0.013 57.1%             |
| Stroke                            | 1.16 (0.81-1.66)   |            | 4           | 5           | 22.79%  | 0.112 49.9%             |
| Cancer                            | 0.94 (0.80-1.10)   |            | 6           | 3           | 18.23%  | 0.183 36.5%             |
| Chronic kidney disease            | 3.49 (2.36-5.15)   |            | 14          | 4           | 18.13%  | 0.001 71.7%             |
| Cardiovascular CVD                | 1.31 (1.24-1.40)   |            | 11          | 10          | 16.39%  | 0.707 0.006             |
| Congestive heart failure          | 1.43 (0.85-2.41)   |            | 7           | 4           | 12.69%  | 0.015 70.7%             |
| COPD                              | 0.83 (0.66-1.03)   |            | 17          | 3           | 33.57%  | 0.001 59.6%             |
| Coronary artery disease           | 1.27 (1.08-1.49)   |            | 8           | 6           | 31.18%  | 0.173 32.1%             |
| Systolic heart failure            | 1.02 (0.66-1.57)   |            | 4           | 3           | 52.12%  | 0.005 51.5%             |
| Immunosuppression                 | 1.16 (0.90-1.50)   |            | 7           | 6           | 10.35%  | 0.001 76.3%             |
| Liver disease                     | 1.68 (1.47-1.90)   |            | 11          | 11          | 3.78%   | 0.159 40.8%             |
| Source of infection               |                    |            |             |             |        |                         |
| Pulmonary                         | 0.77 (0.60-0.99)   |            | 19          | 7           | 46.05%  | 0.038 77.6%             |
| Abdominal                         | 1.44 (1.32-1.58)   |            | 25          | 19          | 30.87%  | 0.021 40.2%             |
| Urinary tract                     | 1.17 (0.86-1.59)   |            | 17          | 14          | 11.14%  | 0.001 60.9%             |
| Unknown                           | 2.01 (1.35-2.98)   |            | 4           | 2           | 6.02%   | 0.39 0.006              |
| Medications                       |                    |            |             |             |        |                         |
| Vasopressors                      | 3.15 (2.00-4.96)   |            | 7           | 1           | 64.61%  | 0.001 81.6%             |
| Diuretics                         | 1.40 (1.13-1.72)   |            | 4           | 3           | 39.77%  | 0.29 0.006              |
| ACEI or ARB                       | 1.71 (1.16-2.52)   |            | 8           | 4           | 25.62%  | 0.001 74.2%             |
| Stain                             | 1.11 (0.69-1.76)   |            | 5           | 1           | 21.77%  | 0.001 81.1%             |
| **Bacteria**                      |                    |            |             |             |        |                         |
| Gram-negative bacteria            | 2.19 (1.52-3.15)   |            | 3           | 1           | 17.26%  | 0.001 75.0%             |
| Gram-positive bacteria            | 1.24 (0.86-1.24)   |            | 4           | 4           | 10.43%  | 0.471 36.3%             |
| **Invasive treatment**            |                    |            |             |             |        |                         |
| Mechanical ventilation            | 1.78 (1.33-2.39)   |            | 33          | 2           | 68.09%  | 0.001 90.5%             |
| Organ transplant                  | 1.96 (1.48-2.61)   |            | 3           | 2           | 3.76%   | 0.77 0.006              |
| Blood transfusion                 | 1.96 (0.81-4.73)   |            | 3           | 2           | 19.46%  | 0.001 63.1%             |

Fig. 2 Meta-analysis of risk factors of AKI

COPD: chronic obstructive pulmonary disease;  ACEI or ARB: Angiotensin converting enzyme inhibitor OR Arteriosclerosis

Negative, statistically significant negative association; Positive, statistically significant positive association; Null, no association; only cells with at least 1 study showing the result include number of studies—all other empty cells indicate no studies with that parameter.
1.35–2.98) with low heterogeneity ($I^2 = 0\%$). The results were still stable with the random-effects model (see Additional file 10).

**Medications**

Vasopressors (from 7 studies; OR: 3.15; 95% CI: 2.00–4.96) and ACEI or ARB (from 8 studies; OR: 1.61; 95% CI: 1.10–2.36) were all identified as risk factors with high levels of heterogeneity ($I^2 \geq 75\%$). The source of heterogeneity was not identified by subgroup analysis and the sensitivity analyses were stable (see Additional file 11).

Pooled data from 5 studies indicated that diuretics were a significant predictor (OR: 1.40; 95% CI: 1.13–1.72) with low levels of heterogeneity ($I^2 = 0\%$). The results remained stable with the random-effects model (see Additional file 12) (Fig. 3).

**Other factors**

Pooled data from 43 studies indicated that male gender was a significant predictor (OR: 1.22; 95% CI: 1.06–1.40) with moderate heterogeneity ($I^2 = 69.80\%$). The source of heterogeneity was not identified by subgroup analysis.
The results arising from sensitivity analyses were consistent (see Additional file 13).

Pooled data from 9 studies indicated that positive blood culture was a significant predictor (OR: 1.60; 95% CI: 1.35–1.89) with moderate heterogeneity ($I^2 = 50.20\%$). The source of heterogeneity was not identified by subgroup analysis. The sensitivity analysis results were consistent (see Additional file 14).

Pooled data from 5 studies indicated that smoking history was a significant predictor (OR: 1.60; 95% CI: 1.09–2.36) with high heterogeneity ($I^2 = 78.30\%$). The source of heterogeneity was not identified by subgroup analysis. The sensitivity analysis results were consistent. After excluding one study with high levels of heterogeneity, the result remained stable (see Additional file 15).

Pooled data from 7 studies indicated that septic shock was a significant predictor (OR: 1.40; 95% CI: 1.13–1.72) with low heterogeneity ($I^2 = 8.2\%$). The results were still stable with the random-effects model (see Additional file 16).

Gram-negative bacteria (from 3 studies; OR: 2.19; 95% CI: 1.52–3.15) and organ transplantation (from 3 studies; OR: 1.96; 95% CI: 1.48–2.61) were all identified as risk factors with low levels of heterogeneity ($I^2 = 0\%$); the results remained stable with the random-effects model (see Additional files 17 and 18).

Pooled data from 24 studies indicated that mechanical ventilation was a significant predictor (OR: 1.64; 95% CI: 1.24–2.16) with high levels of heterogeneity ($I^2 = 88.70\%$). The source of heterogeneity was not identified by subgroup analysis. The sensitivity analysis results were consistent (see Additional file 19) (Fig. 4).

**Tests for publication Bias (Fig. 2)**

Egger's rank correlation test and Egger's linear regression test indicated that there was no publication bias for any of the risk factors ($\geq 7$ studies) except for cardiovascular disease ($P = 0.015$). Due to the limited number of studies ($<7$ studies), publication bias was not evaluated for smoking history, cirrhosis, multiorgan dysfunction ($\geq 3$), unknown infection, the administration of vasoactive drugs, the use of diuretics, and organ transplantation (Fig. 5).

**Discussion**

**Major findings**

To the best of our knowledge, this is the first meta-analysis to provide a comprehensive insight into the risk factors associated with AKI in patients with sepsis. In total, 47 studies, including 55,911 patients with sepsis, were included in this systematic review, along with 46 risk factors. The results showed that 19 factors were significant, including comorbidities, sources of infection, medications, and invasive treatments. Risk factors for S-AKI arise from a wide range of sources, making it difficult to predict and prevent this disease. We found that AKI caused by septic shock had the highest incidence and mortality in patients with sepsis. We also found significant inter-trial heterogeneity in studies exploring the association between sepsis and AKI, thus resulting in reduced evidential power. Inevitably, this has led to controversial opinions regarding the risk factors for AKI in patients with sepsis. We, therefore, hope that more
homogeneous research can be carried out in the future and more reliable conclusions can be obtained.

**Analysis of risk factors**

Risk factors for sepsis-associated AKI can be categorized as pre-sepsis risk factors, sepsis disease-related factors and sepsis-related treatment factors. The pre-sepsis risk factors (e.g., concurrent chronic diseases, gender, age, and smoking history) and sepsis disease itself (e.g., sepsis type, source of infection, and bacterial infection) cannot be altered since they existed at the time of diagnosis. However, these factors can be used to identify patients who are at high risk of AKI, so that timely precautions can be applied accordingly to reduce potential risks in the future. On the other hand, the risk factors associated with sepsis-related treatment can be manually controlled by using efficient strategies (e.g., medication and mechanical ventilation).

**Pre-sepsis risk factors**

Our study showed that multiple chronic comorbidities were associated with the development of AKI in patients with sepsis. Hypertension and diabetes mellitus were the most common risk factors for AKI among all comorbidities; other factors included chronic kidney diseases, cardiovascular diseases, coronary artery diseases, and liver diseases. This may be due to the fact that the majority of patients with sepsis were older adults aged 65 years and older [6, 59]. We found that diabetes mellitus and hypertension were associated with higher risks of AKI; these findings were consistent with those of previous studies [60–63]. Chronic kidney disease has been recognized as a significant risk factor for AKI [64, 65]. Moreover, when AKI occurs in CKD patients, it is more severe and difficult to recover from. There is increasing recognition that AKI and chronic kidney disease (CKD) are closely linked and are likely to promote one another. However, the association between the severity of CKD (e.g., as measured by levels of estimated GFR) and the risk of AKI has not been quantified, although a recent meta-analysis showed that CKD may increase the risk of AKI in patients with diabetes or hypertension. Therefore, in addition to directly increasing the risk of AKI, diabetes mellitus, hypertension, and CKD, could also interact to promote the development of AKI [63]. Furthermore, these three factors are also prevalent risk factors for AKI. Consequently, more attention should be paid to patients with these three risk factors in order to avoid the potential risks of AKI.
Opinions regarding the association between gender and AKI remain controversial, although our study found that male patients may be at a slightly higher risk of AKI compared with their female counterparts. A previous study found that a lower glomerular filtration rate (eGFR) and a higher albumin-creatinine ratio (ACR) were associated with higher AKI risks in both men and women, and that male gender was associated with a higher risk of AKI with a slight attenuation in a lower eGFR but not with a higher ACR [66].

Sepsis-disease-related risk factors
Among the patients with sepsis that were included in the present study, we found that AKI caused by septic shock had the highest incidence and mortality, and that septic shock was also a significant risk factor for AKI. Consequently, more attention should be paid to the prevention of AKI in patients with septic shock.

Our data analysis indicated that pulmonary and abdominal infections were the most common source of infection in patients with sepsis who developed AKI. We also found that both of these conditions were associated with the development of AKI. Abdominal infections could increase the risk of AKI development, although our study found that lung infection was a protective factor for AKI, although further research is needed to elucidate the mechanisms underlying this observation. Considering the high levels of heterogeneity (I² = 77.6%), we performed sensitivity analyses to obtain stable results. Subgroup analysis showed different results when considering Chinese populations and other populations. Pulmonary infection was found to be a risk factor in the Chinese population (OR: 1.62; 95% CI: 1.06–2.49) but was a protective factor in other populations (OR: 0.61; 95% CI: 0.50–0.74). We were cautious about the overall results and the results of our subgroup analysis since there was a lack of reasonable interpretation for these results, as well as heterogeneity among different populations. Further research is required to investigate these issues further.

The specific relationship between the occurrence of AKI and bacterial infection has rarely been reported. Our study found that gram-negative bacteria may represent a risk factor for AKI. However, it remains unclear which gram-negative bacteria could be involved. Only one study showed that Escherichia coli may be associated with the development of AKI [66]. Further research is now needed to investigate this relationship further.

Sepsis-related treatment risk factors
Our study found that diuretics, vasopressors, and ACEI or ARB, could be associated with the occurrence of AKI. Vasoactive drugs are commonly used in patients with sepsis, especially septic shock. Our research found that vasopressors increased the risk of AKI, while the association between AKI and other vasoactive medications remains uncertain. A large cohort study previously showed that ACEI/ARB could be associated with a small increase in the risk of AKI while individual patient characteristics were much more closely correlated with the incidence of AKI [67]. Among patients with CKD, there was no increased risk of developing AKI compared with those who were not exposed to ACEI/ARB, while exposure to ACEI/ARB in patients without CKD increased the risk of AKI. An earlier multi-center prospective study in Shanghai showed that diuretics accounted for 22.2% of all drug-induced cases of AKI, ranked only after antibiotics [68]. The reasons for the association between the use of diuretics and an increased risk of AKI could be interpreted as follows. First, loop diuretics block sodium chloride uptake in the macula densa in a manner that is independent of any effect on sodium and water balance, thereby stimulating the renin-angiotensin-aldosterone system (RAAS) and leading to AKI. Sometimes, AKI is caused by the combined action of diuretics and other drugs, which may include antibiotics, contrast media, ACEI/ARB, and NSAIDs [69]. Another study showed that a triple therapy combination consisting of diuretics with ACEI or ARB and NSAIDs was associated with an increased risk of AKI [70]. However, the high levels of heterogeneity related to these factors cannot be ignored. Furthermore, our subgroup analyses failed to identify the specific sources of such heterogeneity. Therefore, these results should be interpreted with caution. Such heterogeneity may originate from the specific types, duration, and dosage of drugs and their interactions with other drugs. More homogeneous clinical randomized trials should be conducted in patients with sepsis to confirm the specific role of these drugs and their interactions in inducing AKI.

Many studies have confirmed that mechanical ventilation is a risk factor for AKI; our present findings concur with these previous findings [71, 72]. A previous study showed that mechanical ventilation is used in up to 75% of patients in ICU [73]. Our analyses showed that 68% of patients with sepsis who developed AKI also used mechanical ventilation; this proportion is even higher in patients with septic shock and severe sepsis. Therefore, we have to pay special attention to prevent the development of AKI in patients undergoing mechanical ventilation. Hypoxemia, hypercapnia, and excessive positive end-expiratory pressure (PEEP) values during mechanical ventilation are all risk factors for AKI. If there are other risk factors at the same time, AKI is more likely to occur. At present, there is no useful method to prevent or reduce the AKI caused by mechanical ventilation. Some studies have shown that the development of AKI can be reduced by adjusting ventilator parameters,
improving hypoxia status as soon as possible, avoiding persistent hypcapnia, and by using smaller PEEP settings. However, a previous meta-analysis showed that invasive MV could be associated with a threefold increase in the odds of AKI in critically ill patients, and tidal volume (Vt) and PEEP settings do not modify this risk [72]. Therefore, future research should focus on strategies that can reduce the risks of AKI induced by mechanical ventilation.

Limitations
Our study has some limitations that should be considered. First, all of our results were based on unadjusted estimates due to the significant variability of multivariable models across different studies. Therefore, we may have failed to identify independent predictors for AKI in the presence of confounding factors. Secondly, significant heterogeneity was observed for certain risk factors due to varied geographic locations, demographic data, and inconsistent diagnostic criteria for AKI and sepsis. We did not identify the source of this heterogeneity in our subgroup analyses; this issue may have impacted on our results. In addition, due to the small number of studies, heterogeneity and publication bias were not evaluated for certain risk factors.

Conclusion
Our analyses showed that the most common risk factors for S-AKI were septic shock, hypertension, diabetes mellitus, abdominal infection, a history of smoking, positive blood cultures, the use of vasopressors, and mechanical ventilation. Other risk factors included cardiovascular and coronary artery disease, liver disease, unknown infections, the use of diuretics, the use of ACEI or ARB, gram-negative bacteria infections, and organ transplantation. Despite our rigorous methodology, the inherent limitations of the included studies prevented us from reaching definitive conclusions. However, this article is the first systematic review and meta-analysis to investigate the risk factors for AKI development in patients with sepsis. Our findings may facilitate the development of clinical targeted care strategies for the prevention, detection and management of AKI in patients with sepsis.

Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s12882-020-01974-8.

Additional file 1. Checklist.PRIStMA Checklist.
Additional file 2. Fig. Hypertension-Forest plot, Funnel plot, Sensitivity and Subgroup analysis.
Additional file 3. Fig. Diabetes mellitus-Forest plot and Funnel plot.
Additional file 4. Fig. Chronic kidney disease-Forest plot, Funnel plot, Sensitivity and Subgroup analysis.

Abbreviations
AKI: Acute kidney injury; S-AKI: Sepsis-associated acute kidney injury; ARF: Acute renal failure; OR: Odds ratio; CI: Confidence interval; CKD: Chronic kidney disease; KDIGO: Kidney disease improving global outcomes; AKIN: Acute kidney injury network classification; RIFLE: Risk, injury, failure, end stage kidney disease; NSAIDs: Non-steroidal anti-inflammatory drugs; COPD: Chronic obstructive pulmonary disease; ACEI or ARB: Angiotensin converting enzyme inhibitors or Angiotensin receptor blocker; PEEP: Positive end-expiratory pressure; MV: Mechanical ventilation

Acknowledgments
Not applicable.

Authors’ contributions
LJF: study design, data collection, data analysis, writing; XHB: data collection, data analysis, writing; YZW: data collection, data analysis; WLS: study design, writing; LF: Article writing, revise, language retouching. All authors have read and approved the final manuscript.

Availability of data and materials
All data generated or analysed during this study are included in this published article [and its seen Additional files and Supplementary materials].

Ethics approval and consent to participate
Not applicable.

Competing interests
There is no conflict of interest in relation to this study.

Author details
1Department of epidemiology and health statistics, Xiangya School of public health, Central South University, No. 238, Mayuanling Lane, Furong Middle Road, Kaifu District, Changsha City, Hunan Province, China. 2Science and Education Department of Changsha Central Hospital, Changsha, Hunan, China. 3Shanghai Health Development Research Center, Shanghai City, China.
References

1. Alobaidi R, Basu RK, Goldstein SL, Bagshaw SM. Sepsis-associated acute kidney injury. Semin Nephrol. 2015;35(2):11. https://doi.org/10.1016/j.
2. Bagshaw SM, George C, Bellomo R. Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units. Crit Care. 2017;21:118. https://doi.org/10.1186/s13054-016-1135-02.
3. Bagshaw SM, Uichong S, Bellomo R, Moriarty H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, Gibney N, et al. Septic acute kidney injury in critically ill patients: clinical characteristics and outcomes. Clin J Am Soc Nephrol. 2007;2:431–9. https://doi.org/10.2215/CJN.03861006.
4. Bouchard J, Acharya A, Cerda J, Maccariello ER, Madarasu RC, Tolwani AJ, Liang X, Fu P, Liu ZH, Mehta RL. A prospective international multicenter study of AKI in the intensive care unit. Clin J Am Soc Nephrol. 2015;10:1324–31.
5. Hsu YC, Hsu CW. Septic acute kidney injury patients in emergency department: the risk factors and its correlation to serum lactate. Am J Emerg Med. 2019;37:204–8. https://doi.org/10.1016/j.ajem.2019.03.024.
6. Clifford KM, Dy-Boarman EA, Haase KK, Maxvill K, Pass SE, Alvarez CA. Challenges with diagnosing and managing Sepsis in older adults. Expert Rev Anti Infect Ther. 2016;14:231–41. https://doi.org/10.1586/14787210.2016.1135052.
7. Rowe TA, McKay JM. Sepsis in Older Adults. Infect Dis Clin North Am. 2017;31:731–42. https://doi.org/10.1016/j.ijdcli.2017.03.011.
8. Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM consensus conference committee. American College of Chest Physicians/ Society of Critical Care Medicine. Chest. 1992;101:1644–55. https://doi.org/10.1378/chest.101.6.1644.
9. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, et al. 2001 SCCM/ESICM/ACP-ASIM international Sepsis definitions conference. Intensive Care Med. 2003;29:530–8. https://doi.org/10.1007/s00134-003-1750-8.
10. Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic and Septic Shock (3–3). JAMA. 2016;315(8):80–10. https://doi.org/10.1001/jama.2016.0287.
11. Mohor D, Liberati A, Petrovic I, Tallafroz J, Altman DG, Cohen J, et al. 2011 EQUATOR Network meta-statement on systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097. https://doi.org/10.1371/journal.pmed.1000097.
12. Bù X, Zhang L, Chen P, Wu X. Relation of neutrophil-to-lymphocyte ratio to acute kidney injury in patients with sepsis and septic shock: a retrospective study. Int Immunopharmacol. 2019;70:372–7. https://doi.org/10.1016/j.intimp.2019.02.043.
13. Hsu YC, Hsu CW. Septic acute kidney injury patients in emergency department: the risk factors and its correlation to serum lactate. Am J Emerg Med. 2019;37:204–8. https://doi.org/10.1016/j.ajem.2018.05.012.
14. Vilander LM, Vaara ST, Pettila V. Genetic variants in SERPINA4 and SERPINA5, but not BCL2 and SKI3 are associated with acute kidney injury in critically ill patients with septic shock. Crit Care. 2017;21:147. https://doi.org/10.1186/s13054-017-1631-3.
15. Suberviola B, Rodrigo E, Gonzalez-Castro A, Serrano M, Heras M, Castellanos-Ortega A. Association between exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prior to septic shock and acute kidney injury. Med Int. 2017;41:121–7. https://doi.org/10.1016/j.medin.2016.07.010.
16. Fisher J, Russell JA, Bentzer P, Parsons D, Secchia S, Melley KR, Boyd JH, Linder A. Heparin-binding protein (HBP): a causative marker and potential target for heparin treatment of human sepsis-associated acute kidney injury. Shock. 2017;48:313–20. https://doi.org/10.1097/SHK.
17. Vilander LM, Kaunisto MA, Vaara ST, Pettila V. Genetic variants in SERPINA4 and SERPINA5, but not BCL2 and SKI3 are associated with acute kidney injury in critically ill patients with septic shock. Crit Care. 2017;21:147. https://doi.org/10.1186/s13054-017-1631-3.
18. Perez-Fernandez X, Sabater-Riera J, Ballus-Riera J, Cardenas-Campos P, Moreno-Gonzalez G, Alonso-Juste V, Corral-Velez V, Gutierrez-Arambula D, Gumucio-Sangüino V, Betbes-Rozg A, et al. No impact of surviving sepsis campaign care bundles in reducing sepsis-associated acute kidney injury. Clin Nephrol. 2017;88(10):155–61. https://doi.org/10.1046/cnj.2017100194.
19. Pereira M, Rodrigues N, Godinho J, Gameiro J, Neves M, Gouveia J, Costa ESZ, Lopes JA. Acute kidney injury in patients with severe sepsis or septic shock: a comparison between the ‘Risk, injury, failure, loss of kidney function, end-stage kidney disease’ (RIFLE), acute kidney injury network (AKIN) and kidney disease: improving global outcomes (KDIGO) classifications. Clin Kidney J. 2017;10:332–40. https://doi.org/10.1093/ckj/sfw107.
20. Panich T, Chanchareonthana W, Sompon P, Issama-Amphorn J, Hirankarn N, Leelawasanchai A. Urinary exosomal activating transcription factor 3 as the diagnostic biomarker for sepsis-associated acute kidney injury. BMC Nephrol. 2017;18:110. https://doi.org/10.1186/s12882-016-0415-3.
21. Su CM, Cheng HH, Hung CW, et al. The value of serum serial cell adhesion molecules in predicting acute kidney injury after severe sepsis in adults. Clin Chim Acta. 2016;457:86–91. https://doi.org/10.1016/j.clinchim.2016.04.008.
22. Yilmaz H, Calmakin M, Inan O, Darcin T, Akcay A. Can neutrophil-lymphocyte ratio be independent risk factor for predicting acute kidney injury in patients with severe sepsis? Ren Fail. 2015;37:225–9. https://doi.org/10.3109/0886022X.2014.982477.
23. Medeiros P, Nga HS, Menezes P, Bribi R, Balbi A, Ponce D. Acute kidney injury in septic patients admitted to emergency clinic room: risk factors and outcome. Clin Exp Nephrol. 2015;19:859–66. https://doi.org/10.1007/s10157-014-0176-9.
24. Dai X, Zeng Z, Fu C, Zhang S, Cai Y, Chen Z. Diagnostic value of neutrophil gelatinase-associated lipocalin, cystatin C, and soluble triggering receptor expressed on myeloid cells-1 in critically ill patients with sepsis-associated acute kidney injury. Crit Care. 2015;19:223. https://doi.org/10.1186/s13054-015-0941-6.
25. Sood M, Mandelzweig K, Rigato C, Tangri N, Komenda P, Martinka G, Arabi Y, Keenan S, Kumar A, Kumar A. Non-pulmonary infections but not specific pathogens are associated with increased risk of AKI in septic shock. Intensive Care Med. 2014;40:1088–90. https://doi.org/10.1007/s00134-014-3361-1.
26. Peng Q, Zhang L, Ai Y, Zhang L. Epidemiology of acute kidney injury in intensive care septic patients based on the KDIGO guidelines. Chin Med J. 2014;127:1820–6.
37. Patschan D, Heep M, Bier M, Brandhorst G, Schneider S, Muller GA, Kozlok M. CD4+ lymphocyte adenosine triphosphate—a new marker in sepsis with acute kidney injury? BMC Nephrol. 2014;15:203. https://doi.org/10.1186/1471-2369-15-203.

38. Tu Y, Wang H, Sun R, Ni Y, Ma L, Xv X, Hu X, Jiang L, Wu A, Chen X, et al. Urinary neutrin-1 and KIM-1 as early biomarkers for septic acute kidney injury. Ren Fail. 2014;36:1559–63. https://doi.org/10.3109/0886022X.2014.949764.

39. Fan H, Zhao Y, Zhu YH, Song FC. Urine neutrophil gelatinase-associated lipocalin in septic patients with and without acute kidney injury. Ren Fail. 2014;36:1399–403. https://doi.org/10.3109/0886022X.2014.945180.

40. Cho E, Lee JJ, Lim HJ, Oh SW, Jo SK, Cho WY, Kim HK, Lee SY. Soluble CD25 is increased in patients with sepsis-associated acute kidney injury. Nephrology (Carlton). 2014;19:318–24. https://doi.org/10.1111/nep.12230.

41. Terzi I, Papaioannou V, Papanas N, Dragoumanis C, Petala A, Theodorou V, Andreou C, Kallitsis A, Anagnostopoulou F, et al. The use of plasma and urine neutrophil gelatinase-associated lipocalin in critically ill patients with severe sepsis: data from the prospective observational FNNAKI study. Crit Care. 2013;17:295S. https://doi.org/10.1186/cc13161.

42. Legrand M, Dupuis C, Simon C, Gayat E, Mateo J, Lukaszewicz AC, Payen D. Association between systemic hemodynamics and septic acute kidney injury in critically ill patients: a retrospective observational study. Crit Care. 2013;17:R278. https://doi.org/10.1186/cc13133.

43. Cardinal-Fernandez P, Ferrueco A, El-Assar M, Santiago C, Gomez-Gallego F, Martin-Pellarin A, Frutos-Vivar F, Penuelas O, Nin N, Esteban A, et al. Genetic predisposition to acute kidney injury induced by sepsis. J Crit Care. 2013;28:365–70. https://doi.org/10.1016/j.jcrc.2012.11.010.

44. de Geus HR, Fortte G, Betjes MG, van Schaik RH, Groeneveld AB. Time of antimicrobial therapy. Intensive Care Med. 2012;38:391–401. https://doi.org/10.1007/s00134-010-1887-4.

45. Martensson J, Bell M, Oldner A, Xu S, Venge P, Martling CR. Neutrophil gelatinase-associated lipocalin in adult septic patients with and without acute kidney injury. Intensive Care Med. 2010;36:1333–40. https://doi.org/10.1007/s00134-010-1887-4.

46. Yang RL, Wang XT, Liu DW. The hemodynamic characteristic and prognosis significance of acute kidney injury caused by septic shock. Zhonghua Nei Ke Za Zhi. 2009;48(9):715–9.

47. Lopes JA, Jorge S, Resina C, Santos C, Pereira A, Neves J, Antunes F, Prata MM. Acute kidney injury in patients with sepsis: a contemporary analysis. Int J Infect Dis. 2009;13:176–81. https://doi.org/10.1016/j.ijid.2008.05.1231.

48. Bagshaw SM, Lapinsky S, Dial S, Arabi Y, Dodek P, Wood G, Ellis P, Guzman J, Marshall J, Parillo JE, et al. Acute kidney injury in septic shock: clinical outcomes and impact of duration of hypotension prior to initiation of antimicrobial therapy. Intensive Care Med. 2009;35:871–81. https://doi.org/10.1007/s00134-008-1367-2.

49. Payen D, Bajwa E, Thompson BT, Srivastava S, Dore GJ, Payen D, Lukaszewicz AC, Legrand M, Gayat E, Mateo J, et al. Acute kidney injury and sepsis: a multicentre evaluation. Crit Care. 2008;12:847. https://doi.org/10.1186/cc6863.

50. Rowe TA, McKoy JM. Sepsis in Older Adults. Infect Dis Clin N Am. 2017;31:731–42. https://doi.org/10.1016/j.idc.2017.07.010.

51. Girman CJ, Kou TD, Brodovicz K, Alexander CM, O’Neill EA, Engel S, Williams-Herman DE, Katz L. Risk of acute renal failure in patients with type 2 diabetes mellitus. Diabet Med. 2012;29:614–21. https://doi.org/10.1111/j.1464-5491.2011.03948.x.

52. Sathananathan M, Sathananathan A, Jeganathan N. Characteristics and outcomes of patients with and without type 2 diabetes mellitus and pulmonary Sepsis. J Intensive Care Med. 2019;34:585–906. https://doi.org/10.1177/0886022X1883910.

53. Greenberg N, Roberts WL, Bachmann LM, Wright EC, Dalton RN, Zakowski MJ, Miller WG. Specificity characteristics of 7 commercial creatinine measurement procedures by enzymatic and Jaffe method principles. Clin Chem. 2012;58:391–401. https://doi.org/10.1373/clinchem.2011.172288.

54. James MT, Grams ME, Woodward M, Elley CR, Green JA, Wheeler DC, de Jong P, Gansvoort RT, Levey AS, Warnock DG, et al. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. Am J Kidney Dis. 2015;65:602–12. https://doi.org/10.1053/j.ajkd.2015.02.338.

55. Liu et al. BMC Nephrology 2020;21:318.

56. He L, Wei Q, Liu J, Yi M, Liu Y, Liu H, Sun L, Peng Y, Liu F, Venkatachalam MA, et al. ABi on CKD: heightened injury, suppressed repair, and the underlying mechanisms. Kidney Int. 2017;92:1071–83. https://doi.org/10.1016/j.kint.2017.06.030.

57. Grams ME, Sang Y, Ballew SH, Gansvoort RT, Kimm H, Kovesdy CP, Naimark D, Olen C, Smith DH, Coresh J, et al. A Meta-analysis of the Association of Estimated GFR, albuminuria, age, race, and sex with acute kidney injury. Am J Kidney Dis. 2015;66:391–601. https://doi.org/10.1053/j.ajkd.2015.02.337.

58. Mansfield KE, Nitch G, Smith B, et al. Preservation of renin-angiotensin system blockers and risk of acute kidney injury a population-based cohort study. BMJ Open. 2016;6(1):e012690. https://doi.org/10.1136/bmjopen-2016-012690.

59. Che ML, Yan YC, Zhang Y, et al. Analysis of drug-induced acute renal failure in Shanghai. Zhonghua Yi Xue Za Zhi. 2009;89(17):744–9.

60. Wu X, Zhang W, Ren H, Chen X, Xie J, Chen N. Diuretics associated acute kidney injury: clinical and pathological analysis. Ren Fail. 2014;36(7):1051–5. https://doi.org/10.3109/0886022X.2014.917560.

61. Camin RM, Cols M, Chevarria JL, et al. Acute kidney injury secondary to a combination of renin-angiotensin system inhibitors, diuretics and NSAIDs: “the triple whammy”. Nephrology. 2015;35(2):197–206. https://doi.org/10.1111/nep.12502.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.